Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer.

MLA

Li, Jiahui, et al. “Combination of Multivalent DR5 Receptor Clustering Agonists and Histone Deacetylase Inhibitors for Treatment of Colon Cancer.” Journal of Controlled Release, vol. 376, Dec. 2024, pp. 1014–24. EBSCOhost, https://doi.org/10.1016/j.jconrel.2024.10.062.

APA

Li, J., Arnold, J., Sima, M., Al Faruque, H., Galang, J., Hu-Lieskovan, S., Kopeček, J., & Yang, J. (2024). Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. Journal of Controlled Release, 376, 1014–1024. https://doi.org/10.1016/j.jconrel.2024.10.062

Chicago

Li, Jiahui, Jaden Arnold, Monika Sima, Hasan Al Faruque, Jacob Galang, Sophia Hu-Lieskovan, Jindřich Kopeček, and Jiyuan Yang. 2024. “Combination of Multivalent DR5 Receptor Clustering Agonists and Histone Deacetylase Inhibitors for Treatment of Colon Cancer.” Journal of Controlled Release 376 (December): 1014–24. doi:10.1016/j.jconrel.2024.10.062.